Praxis Precision Medicine Financials - Benzinga

Praxis Precision Medicines Inc

PRAXNASDAQ

Trade with Public

Trade with Public

$281.79

-0.33-0.12%

$282.00

-0.12-0.04%

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

Praxis Precision Medicine Financials

Praxis Precision Medicine (PRAX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate

Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(2.87) per share which beat the analyst consensus estimate of $(3.65) by 21.37 percent. This is a 13.29 percent increase over losses of $(3.31) per

Benzinga Newsdesk

PRO
Praxis Precision Medicine Q1 EPS $(3.20) Beats $(3.50) Estimate

Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(3.20) per share which beat the analyst consensus estimate of $(3.50) by 8.57 percent. This is a 2.74 percent increase over losses of $(3.29) per

Benzinga Newsdesk

Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results

Avi Kapoor

Earnings Breakdown: Praxis Precision Medicine Q4

Benzinga Insights

PRO
Praxis Precision Medicine Q4 EPS $(3.50) Misses $(3.08) Estimate

Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(3.50) per share which missed the analyst consensus estimate of $(3.08) by 13.67 percent. This is a 19.05 percent decrease over losses of $(2.94) per

Benzinga Newsdesk

Earnings Scheduled For February 19, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved